ReviewBMC pharmacology & toxicology2018
Polymyxin B-induced skin hyperpigmentation: a rare case report and literature review.
Review in BMC pharmacology & toxicology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- A rare drug reaction: Toxic epidermal necrolysis following polymyxin B administration in a post-Bentall procedure.Indian journal of pharmacology · 2026Article
- A Rare Case of Polymyxin B Induced Transverse Melanonychia Affecting All 20 Nails.Acta dermato-venereologica · 2025Article
- Comparison of Efficacy and Safety of Colistimethate Sodium and Polymyxin B in the Treatment of Bloodstream Infection Caused by Carbapenem-Resistant Gram-Negative Bacteria: A Retrospective Study.Infection and drug resistance · 2025Article
- Case Report: Polymyxin B-induced anaphylactic shock.Frontiers in pharmacology · 2025Article
- Article
- Rare occurrence of polymyxin B-induced hyperpigmentation in a child with ventriculitis.BMJ case reports · 2023Article
- Clinical efficacy and nephrotoxicity of intravenous colistin sulfate in the treatment of carbapenem-resistant gram-negative bacterial infections: a retrospective cohort study.Annals of translational medicine · 2022Article
- Proteomic Response Revealed Signaling Pathways Involving in the Mechanism of Polymyxin B-Induced Melanogenesis.Microbiology spectrum · 2022Article
- Pharmacokinetics and pharmacodynamics of peptide antibiotics.Advanced drug delivery reviews · 2022Review
- Intrathecal or Intraventricular Tigecycline Therapy for Central Nervous System Infection Associated with Carbapenem-ResistantInfection and drug resistance · 2022Article
- ADR in Journals: Are They Translated into Regulatory Frameworks?Current drug safety · 2022Article
- Outcome of Using Intraventricular Plus Intravenous Polymyxin B in Post-neurosurgical Patients With Multi/Extensively Drug-Resistant Gram-Negative Bacteria-Induced Intracranial Infection.Frontiers in medicine · 2022Article
- The polypeptide antibiotic polymyxin B acts as a pro-inflammatory irritant by preferentially targeting macrophages.The Journal of antibiotics · 2022Article
- Rescuing the Last-Line Polymyxins: Achievements and Challenges.Pharmacological reviews · 2021Review
- Successful Treatment With Intrathecal and Intravenous Polymyxin B-Based Combination Against MDRFrontiers in pediatrics · 2021Article
- The Difference Between Polymyxin B and Polymyxin E in Causing Skin Hyerpigmentation.Frontiers in pharmacology · 2021Article
- An evaluation of the clinical features of measles virus infection for diagnosis in children within a limited resources setting.BMC pediatrics · 2020Article
- Skin Hyperpigmentation in Coronavirus Disease 2019 Patients: Is Polymyxin B the Culprit?Frontiers in pharmacology · 2020Article
- Cutaneous Hyperpigmentation Secondary to High-Dose Tigecycline: A Case Report.Therapeutic advances in infectious diseaseArticle
- COVID-19: The experience from Beijing, China.Clinics in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolymyxin B (PMB), which is regarded as the ultimate antibacterial treatment against some intractable gram-negative bacteria with its outstanding anti-bacterial activities, inflicts several adverse effects on patients. However, skin hyperpigmentaion (SH) induced by PMB is very rare. Here, we report a case of polymyxin B-induced skin hyperpigmentation (PMB-iSH) in a 21-year-old female. To the best of our knowledge, this is the first case of PMB-iSH in China. CASE PRESENTATION: A 21-year-old female patient with sepsis received the administration of PMB by intravenous injection for the treatment of multi-drug resistant Klebsiella pneumoniae (MDR-KP) infection. She later suffered from a rare adverse drug reaction (ADR), namely PMB-iSH, after 5-day PMB administration during her treatment. There were multiple red rashes spread on the whole body skin at first. With the rashes fading away, SH with dark round spots appeared, associated with no pain or pruritus. The skin of the head and neck was darkened evidently, and dark brown spots were spread on the skin of trunk and limbs. About a month after her admission, urged by the relatives, the patient was transferred back to the local hospital for further treatment in the end, and her skin color didn't recover to the previous state at that time.
conclusionBoth our case and the literature review highlight that PMB can give rise to SH indeed. Clinicians and pharmacists should attach great importance to this rare pigmentary disorder and further investigation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.